| Followers | 21 |
| Posts | 946 |
| Boards Moderated | 0 |
| Alias Born | 07/20/2020 |
Tuesday, September 27, 2022 6:32:18 PM
Dude- Your due diligence is appreciated and your knowledge is unrelenting. The only part I understood is when you said you don't have time to respond to the third prompt.
ps. I get the glutathione relevance, the NAC comparison, the lessening of myocardial repercussion, and a host of other positives, but what I think we need most is just plain and simple dumb luck. A few patients here could swing this at 210, so unblinding the rest seems to be in order. I trust the FDA will like the 210 to get us to the next phase. Wash, scrub, clean, prepare, and shoot that sh-t off now.
pps. Let's get em.
ps. I get the glutathione relevance, the NAC comparison, the lessening of myocardial repercussion, and a host of other positives, but what I think we need most is just plain and simple dumb luck. A few patients here could swing this at 210, so unblinding the rest seems to be in order. I trust the FDA will like the 210 to get us to the next phase. Wash, scrub, clean, prepare, and shoot that sh-t off now.
pps. Let's get em.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
